DE69635480D1 - Apoptosis induzierendes cytokin - Google Patents

Apoptosis induzierendes cytokin

Info

Publication number
DE69635480D1
DE69635480D1 DE69635480T DE69635480T DE69635480D1 DE 69635480 D1 DE69635480 D1 DE 69635480D1 DE 69635480 T DE69635480 T DE 69635480T DE 69635480 T DE69635480 T DE 69635480T DE 69635480 D1 DE69635480 D1 DE 69635480D1
Authority
DE
Germany
Prior art keywords
trail
cells
cytokin
apoptosis
inductive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635480T
Other languages
English (en)
Other versions
DE69635480T2 (de
Inventor
R Wiley
G Goodwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27052201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69635480(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE69635480D1 publication Critical patent/DE69635480D1/de
Application granted granted Critical
Publication of DE69635480T2 publication Critical patent/DE69635480T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L27/00—Modulated-carrier systems
    • H04L27/18—Phase-modulated carrier systems, i.e. using phase-shift keying
    • H04L27/22—Demodulator circuits; Receiver circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69635480T 1995-06-29 1996-06-25 Apoptosis induzierendes cytokin Expired - Lifetime DE69635480T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US496632 1990-03-21
US49663295A 1995-06-29 1995-06-29
US54836895A 1995-11-01 1995-11-01
US548368 1995-11-01
PCT/US1996/010895 WO1997001633A1 (en) 1995-06-29 1996-06-25 Cytokine that induces apoptosis

Publications (2)

Publication Number Publication Date
DE69635480D1 true DE69635480D1 (de) 2005-12-29
DE69635480T2 DE69635480T2 (de) 2006-08-17

Family

ID=27052201

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69638346T Expired - Lifetime DE69638346D1 (de) 1995-06-29 1996-06-25 Cytokin welches Apoptose induziert
DE69635480T Expired - Lifetime DE69635480T2 (de) 1995-06-29 1996-06-25 Apoptosis induzierendes cytokin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69638346T Expired - Lifetime DE69638346D1 (de) 1995-06-29 1996-06-25 Cytokin welches Apoptose induziert

Country Status (16)

Country Link
US (1) US5763223A (de)
EP (2) EP1666591B1 (de)
JP (1) JP4435304B2 (de)
KR (2) KR100510234B1 (de)
AT (2) ATE310813T1 (de)
AU (1) AU708239B2 (de)
CA (1) CA2225378C (de)
DE (2) DE69638346D1 (de)
DK (2) DK0835305T3 (de)
ES (2) ES2362191T3 (de)
HK (2) HK1010215A1 (de)
IL (6) IL122408A0 (de)
NO (1) NO321707B1 (de)
NZ (1) NZ311982A (de)
PT (1) PT1666591E (de)
WO (1) WO1997001633A1 (de)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US20040048340A1 (en) * 1996-03-14 2004-03-11 Human Genome Sciences, Inc. Apoptosis inducing molecule I
JP2000515727A (ja) * 1996-06-07 2000-11-28 アムジエン・インコーポレーテツド 腫瘍壊死因子関連ポリペプチド
DE69738841D1 (de) * 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) * 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
PT1012274E (pt) * 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
US20020009467A1 (en) 1997-01-29 2002-01-24 Shozo Koyama Antigenic substance inductor, vaccine precursor, vaccine, antibody, neutralizing antibody, antitoxin, idiotype antibody and/or anti-idiotype antibody which is induced by its idiotype antibody
JP3813682B2 (ja) * 1997-01-29 2006-08-23 小山 省三 ワクチン前駆体およびワクチン
CA2280231A1 (en) 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
US7528239B1 (en) * 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
NZ337795A (en) * 1997-03-17 2001-06-29 Human Genome Sciences Inc Death domain containing receptor 5 and it's use in the treatment of DR5 related disease
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
DK0975754T4 (en) * 1997-04-16 2016-03-21 Amgen Inc Osteoprotegerin binding proteins and their receptors
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
ES2293682T5 (es) * 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
EP2083079A1 (de) * 1997-06-18 2009-07-29 Genentech, Inc. Apo-2DcR
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
AU8400398A (en) * 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
FR2766713B1 (fr) * 1997-08-04 1999-09-24 Bio Merieux Facteur proteique associe a une maladie neuro-degenerative et/ou auto-immune et/ou inflammatoire
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
JP2002516069A (ja) * 1997-09-30 2002-06-04 ファルマシア・アンド・アップジョン・カンパニー Ｔｎｆ関連死リガンド
AU760010B2 (en) * 1997-11-18 2003-05-08 Genentech Inc. DNA19355 polypeptide, a tumor necrosis factor homolog
US7019119B2 (en) * 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
EP1045906B1 (de) * 1998-01-15 2008-10-15 Genentech, Inc. Apo-2 ligand
US20040120947A1 (en) * 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US20040180049A1 (en) * 1998-01-26 2004-09-16 Genentech, Inc. DR4 antibodies and uses thereof
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP1941905A1 (de) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
ATE398464T1 (de) * 1998-03-27 2008-07-15 Genentech Inc Synergie zwischen apo-2 ligand und antikörper gegen her-2
PT1086138E (pt) 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
WO2000026228A1 (en) * 1998-11-02 2000-05-11 Clontech Laboratories, Inc. Gene and protein for regulation of cell death
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US7232889B2 (en) * 1999-03-08 2007-06-19 Genentech, Inc. PRO300 antibodies
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
ES2421720T3 (es) 1999-04-12 2013-09-05 Genentech Inc Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican
AU3923000A (en) * 1999-04-16 2000-11-02 Amgen, Inc. Agp-1 fusion protein compositions and methods
EP1867719A3 (de) * 1999-06-02 2008-03-19 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
EP2339003A3 (de) * 1999-06-28 2011-10-19 Genentech, Inc. APO-2 LIGAND substitutionnelle Varianten
US6444640B1 (en) * 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
CA2386002A1 (en) * 1999-09-30 2001-04-05 The Trustees Of The University Of Pennsylvania Trail: an inhibitor of autoimmune inflammation and cell cycle progression
WO2001045730A2 (en) 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor
EP1250055B1 (de) * 2000-01-24 2010-09-15 University Of Louisville Research Foundation, Inc. Immunmodulation mit rezeptorinduziertem tod durch apoptosis
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
DE60028830T2 (de) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US6900185B1 (en) 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
US7238360B2 (en) * 2000-06-30 2007-07-03 Unversity Of Louisville Research Foundation, Inc. Alteration of cell membrane with B7
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
DE60133479T2 (de) 2000-10-20 2009-04-16 Chugai Seiyaku K.K. Modifizierter tpo-agonisten antikörper
WO2002079377A2 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
GB0113920D0 (en) 2001-06-07 2001-08-01 Sterix Ltd Composition
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
PT1409544E (pt) 2001-07-03 2009-09-16 Genentech Inc Anticorpos de dr4 humanos e suas utilizações
JP2005502645A (ja) * 2001-08-08 2005-01-27 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 細胞特異的プロモーターからの発現を増幅するための方法
JP2005508162A (ja) 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
EP2322165A1 (de) 2001-11-13 2011-05-18 Genentech, Inc. Apo2-Ligand/TRAIL-Formulierungen
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
JP2005516958A (ja) * 2001-12-20 2005-06-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
AU2003220529B2 (en) 2002-03-27 2006-09-07 Immunex Corporation Methods for increasing polypeptide production
JP4761710B2 (ja) * 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
EP1556076A4 (de) 2002-06-24 2009-07-08 Genentech Inc Apo-2 ligand/trail-varianten und ihre verwendungszwecke
EP2269656B1 (de) 2002-07-15 2014-08-20 Board Of Regents, The University Of Texas Ausgewählte antikörper mit bindung an aminophospholipide und ihre verwendung bei der behandlung von krebs
WO2004052292A2 (en) * 2002-12-06 2004-06-24 University Of South Florida Histone deacetylase inhibitor enhancement of trail-induced apoptosis
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
CA2539000A1 (en) * 2003-09-18 2005-03-24 Novartis Ag Combination of a histone deacetylase inhibitor with a death receptor ligand
EP1688498B1 (de) 2003-11-03 2011-03-09 Beijing Sunbio Biotech Co., Ltd. Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
US20080206229A1 (en) 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
KR20170102377A (ko) 2004-01-22 2017-09-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
WO2005082934A2 (en) * 2004-02-20 2005-09-09 Five Prime Therapeutics, Inc. Novel apo2l and il-24 polypeptides, polynucleotides, and methods of their use
PL1733037T3 (pl) 2004-03-11 2015-04-30 Genentech Inc Sposób wytwarzania polipeptydów
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
CN101035912A (zh) 2004-08-06 2007-09-12 健泰科生物技术公司 使用生物标志的测定法和方法
AU2005271249A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
EP1802660A2 (de) * 2004-09-08 2007-07-04 Genentech, Inc. Verfahren zur verwendung von todesrezeptorliganden und cd20-antikörpern
JP2008513367A (ja) * 2004-09-08 2008-05-01 ジェネンテック・インコーポレーテッド デスレセプターリガンド及びｃｄ２０抗体の使用方法
EP1645875A1 (de) * 2004-10-08 2006-04-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnose und Therapie von Zellproliferationskrankheiten die durch TRAIL Resistenz Apoptose gekennzeichnet sind
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060228352A1 (en) * 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
ZA200800974B (en) 2005-08-16 2009-11-25 Genentech Inc Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
CA2619654A1 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
US20100047783A1 (en) * 2006-06-20 2010-02-25 El-Diery Wafik S Small molecule modulators of p53 family signaling
WO2008088582A2 (en) * 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Methods and materials related to trail isoforms
EP2136831B1 (de) 2007-03-02 2012-09-12 The Cleveland Clinic Foundation Anti-angiogene peptide
EP2484691B1 (de) 2007-07-10 2016-01-13 Apogenix GmbH TNF-Superfamilie-Collectinfusionsproteine
AU2013203061B2 (en) * 2007-07-10 2016-07-28 Apogenix Ag TNF superfamily collectin fusion proteins
WO2009025743A2 (en) * 2007-08-17 2009-02-26 University Of Massachusetts Medical School Use of trail compositions as antiviral agents
CN101157729B (zh) * 2007-10-23 2011-01-12 南京大学 一种肿瘤坏死因子相关凋亡配体变体及其应用
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
WO2010062904A2 (en) 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
ES2356880B8 (es) 2009-08-21 2012-10-30 Universidad De Zaragoza Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail.
CN102686606A (zh) * 2009-10-09 2012-09-19 阿纳福公司 结合il-23r的多肽
CN102821778B (zh) * 2010-04-01 2014-07-30 韩国生命工学研究院 含有tip41表达或活性抑制剂作为靶基因或trail敏化剂的用于增强trail敏感性的组合物
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
SG187198A1 (en) 2010-08-05 2013-03-28 Amgen Inc Dipeptides to enhance yield and viability from cell cultures
SI2646464T1 (sl) 2010-12-03 2015-07-31 Adamed Sp. Z.O.O. Fuzijski protein proti raku
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
PL394618A1 (pl) 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
US20140178398A1 (en) 2011-05-03 2014-06-26 Genentech, Inc Vascular disruption agents and uses thereof
LT2837680T (lt) 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
CN102908612A (zh) * 2011-08-02 2013-02-06 北京诺赛基因组研究中心有限公司 TRAIL截短型变异体活化NF-κB和在炎症反应中的应用
BR112014004591A2 (pt) 2011-09-02 2017-03-28 Amgen Inc produto farmacêutico de análise da exposição à luz de um produto farmacêutico
JP5956580B2 (ja) * 2011-09-16 2016-07-27 北京沙▲東▼生物技▲術▼有限公司Ｂｅｉｊｉｎｇ Ｓｕｎｂｉｏ Ｂｉｏｔｅｃｈ Ｃｏ．， Ｌｔｄ． Ｔｒａｉｌ／ａｐｏ２ｌの円順列変異形を含む融合タンパク質、コーディング遺伝子およびそれらの使用
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
PL223487B1 (pl) 2011-12-28 2016-10-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
KR20150107742A (ko) * 2012-12-11 2015-09-23 자피오텍 게엠베하 흑색종 세포를 퇴치하기 위한 델피니딘
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014159441A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Removal of leaked affinity purification ligand
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
ES2644022T3 (es) 2013-03-14 2017-11-27 Bristol-Myers Squibb Company Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
US11130980B2 (en) 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
CN112481337A (zh) 2014-01-13 2021-03-12 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
EA202190244A3 (ru) 2014-01-29 2021-08-31 Эмджен Инк. Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
ES2709994T3 (es) 2014-06-04 2019-04-22 Amgen Inc Métodos de recolección en cultivos de células de mamífero
MX2017006463A (es) 2014-11-19 2018-04-20 Amgen Inc Cuantificacion de porcion de glicano en glicoproteinas recombinantes.
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
CN108601819B (zh) 2015-12-17 2022-03-15 约翰霍普金斯大学 用死亡受体激动剂改善系统性硬化症
KR20180098625A (ko) 2015-12-30 2018-09-04 제넨테크, 인크. 분해가 감소된 폴리소르베이트를 갖는 제형
JP6725699B2 (ja) * 2016-02-05 2020-07-22 エスエルビゲン・インコーポレイテッドＳｌｂｉｇｅｎ Ｉｎｃ． Ｔｒａｉｌとｃｄを発現している間葉系幹細胞およびその使用
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
KR101739703B1 (ko) * 2016-09-13 2017-05-24 (주) 어드밴스드 엔티 Trail 기반 뇌염 감별진단 방법 및 장치
US11519007B2 (en) 2019-02-22 2022-12-06 Arizona Board Of Regents On Behalf Of Arizona State University Tumor-navigating, self-eradicating, trail-armed salmonella for precision cancer therapy
WO2023129974A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
EP0276846A3 (de) 1987-01-29 1989-07-26 Zymogenetics, Inc. Derivate des koloniestimulierenden Faktors
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
ES2055907T3 (es) 1989-03-07 1994-09-01 Genentech Inc Conjugados covalentes de lipidos y oligonucleotidos.
EP0471796A4 (en) 1989-05-10 1993-05-05 Sloan Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
DE69027443T2 (de) 1989-10-24 1998-03-19 Gilead Sciences Inc Oligonukleotidanaloga mit neuartigen bindungen
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5512435A (en) 1993-02-05 1996-04-30 Renschler; Markus F. Receptor-binding antiproliferative peptides
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5620889A (en) 1993-10-14 1997-04-15 Immunex Corporation Human anti-Fas IgG1 monoclonal antibodies
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO1997033899A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP2000515727A (ja) * 1996-06-07 2000-11-28 アムジエン・インコーポレーテツド 腫瘍壊死因子関連ポリペプチド

Also Published As

Publication number Publication date
PT1666591E (pt) 2011-06-01
HK1092836A1 (en) 2007-02-16
US5763223A (en) 1998-06-09
EP0835305A1 (de) 1998-04-15
NO976045D0 (no) 1997-12-22
IL149261A0 (en) 2002-11-10
DE69638346D1 (de) 2011-05-05
IL122408A0 (en) 1998-06-15
NO321707B1 (no) 2006-06-26
DK1666591T3 (da) 2011-05-23
HK1010215A1 (en) 1999-06-17
KR19990028264A (ko) 1999-04-15
NZ311982A (en) 1999-08-30
IL149261A (en) 2006-09-05
IL190068A0 (en) 2008-08-07
DK0835305T3 (da) 2006-02-13
CA2225378C (en) 2012-04-17
IL122408A (en) 2008-03-20
CA2225378A1 (en) 1997-01-16
KR101004174B1 (ko) 2010-12-24
KR20050085914A (ko) 2005-08-29
KR100510234B1 (ko) 2005-11-25
ES2253753T3 (es) 2006-06-01
AU6340796A (en) 1997-01-30
ATE310813T1 (de) 2005-12-15
IL184699A0 (en) 2007-12-03
ES2362191T3 (es) 2011-06-29
EP1666591B1 (de) 2011-03-23
WO1997001633A1 (en) 1997-01-16
EP1666591A1 (de) 2006-06-07
NO976045L (no) 1998-03-02
IL184699A (en) 2011-11-30
EP0835305A4 (de) 2002-02-06
DE69635480T2 (de) 2006-08-17
MX9710399A (es) 1998-03-31
AU708239B2 (en) 1999-07-29
JPH11508445A (ja) 1999-07-27
ATE503013T1 (de) 2011-04-15
EP0835305B1 (de) 2005-11-23
JP4435304B2 (ja) 2010-03-17

Similar Documents

Publication Publication Date Title
DE69635480D1 (de) Apoptosis induzierendes cytokin
DK0574512T3 (da) Omdirigering af cellulær immunitet med receptorkimærer
DK1009832T3 (da) Cytokin betegnet LERK-6
FI972390A (fi) Sytokiini nimeltä Lerk-7
FI885543A (fi) Dna-segment, polypeptider och anti-kroppar anslutande till human vaevnadsfaktor.
FI961251A (fi) Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet
DK0757717T3 (da) Papillomavirusvacciner
ES2123006T3 (es) Levaduras recombinantes altamente estables para la produccion de proteinas recombinantes.
DK0663010T3 (da) Fremgangsmåde til forøgelse af sekretion af overudtrykte proteiner
ATE87655T1 (de) Markierer der t-zelle aktivierung.
ATE386101T1 (de) Expressionsplasmide, durch einen osmb promoter reguliert
DK346385A (da) Genetiske sekvenser, hermed kodede interferon-peptider af type i og organismer, der producerer disse
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
NO971378L (no) Cytokin betegnet LERK-6
NZ215820A (en) Hepatitis b antigen formed by recombinant dna techniques
SU1515698A1 (ru) Рекомбинантная плазмидная днк, кодирующая синтез hbs ag вируса гепатита b, и штамм вируса осповакцины - продуцент hbs ag вируса гепатита b

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings